Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Docetaxel in Recurrent or Metastatic Breast Cancer
NCT00054275Phase 2Completed
- Start
- Dec 2002
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in breast cancer. Primary endpoints: Objective Response at 6 months and Disease Stabilization at 6 months. Started Dec 2002; status: completed.
02
Drugs
erlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00054275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054275.